Concourse Financial Group Securities, Inc. Hepion Pharmaceuticals, Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $1.64 Billion
  • Q3 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$0.31 - $1.06 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023
BUY
$0.27 - $11.9 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022
BUY
$0.51 - $10.4 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$0.57 - $1.22 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$0.93 - $1.29 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$1.14 - $1.58 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$1.39 - $2.1 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$1.56 - $2.26 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021
BUY
$1.77 - $2.98 $0 - $0
0 New
0 $0
Q4 2020

Feb 02, 2021
BUY
$1.58 - $3.64 $0 - $0
0 New
0 $0
Q3 2020

Nov 13, 2020
BUY
$2.84 - $4.59 $0 - $0
0 New
0 $0
Q2 2020

Aug 13, 2020
BUY
$1.31 - $3.09 $0 - $0
0 New
0 $0
Q1 2020

May 13, 2020
BUY
$1.15 - $5.74 $0 - $0
0 New
0 $0
Q4 2019

Feb 14, 2020
BUY
$2.25 - $6.99 $0 - $0
0 New
0 $0
Q3 2019

Nov 13, 2019
BUY
$2.09 - $4.12 $0 - $0
0 New
0 $0

About Hepion Pharmaceuticals, Inc.

HEPA Quotes by TradingView
  • Ticker HEPA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,229,600
  • Market Cap $51.8M
  • Description
  • Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...
More about HEPA
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email